Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 8/20 | 0.75 |
| ▸ | HTR3A | P46098 | 2/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2197969 | 1.00 | CHRNA7 (0.75) | CHRNA7HTR3APOLBRAB9A | |
| Hydrochloric Acid SCHEMBL2890029 | 0.99 | CHRNA7 (0.73) | CHRNA7HTR3APOLBRAB9A | |
| Hydrochloric Acid SCHEMBL2893318 | 0.99 | CHRNA7 (0.73) | CHRNA7HTR3APOLBRAB9A | |
| SCHEMBL4197731 | 0.87 | CHRNA7 (0.60) | CHRNA7HTR3APOLB | |
| SCHEMBL4197728 | 0.87 | CHRNA7 (0.60) | CHRNA7HTR3APOLB | |
| SCHEMBL2893440 | 0.86 | CHRNA7 (0.83) | CHRNA7HTR3A | |
| SCHEMBL1091429 | 0.86 | CHRNA7 (1.00) | CHRNA7HTR3A | |
| SCHEMBL2889527 | 0.86 | CHRNA7 (0.83) | CHRNA7HTR3A | |
| SCHEMBL6661124 | 0.85 | CHRNA7 (1.00) | CHRNA7HTR3A | |
| SCHEMBL6654170 | 0.85 | CHRNA7 (1.00) | CHRNA7HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20220347166-A1 | Schizophrenic Disorder Treatment using Combination Therapy | CAMBRIDGE COGNITION LIMITED (GB) | 2022-11-03 | — | — | US | claimed |
| CN-114845717-A | Treatment of schizophrenia disorders using combination therapy | 剑桥认知有限公司 | 2022-08-02 | — | — | CN | claimed |
| WO-2021078810-A1 | SCHIZOPHRENIC DISORDER TREATMENT USING COMBINATION THERAPY | CAMBRIDGE COGNITION LTD. (GB) | 2021-04-29 | — | — | WO | claimed |
| US-20190105315-A1 | COMPOSITIONS AND METHODS FOR TREATMENT RELATED TO FALL AND FALL FREQUENCY IN NEURODEGENERATIVE DISEASES | Neurocea, LLC | 2019-04-11 | — | — | US | claimed |
| EP-2678315-B1 | (Pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nAChR | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-16 | — | — | EP | claimed |
| EP-2504333-B1 | Morpholinothiazoles as alpha 7 positive allosteric modulators | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-15 | — | — | EP | claimed |
| US-8637510-B2 | Morpholinothiazoles as alpha 7 positive allosteric modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-28 | — | — | US | claimed |
| EP-2678315-A2 | (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR | Janssen Pharmaceutica, N.V. (BE) | 2014-01-01 | — | — | EP | claimed |
| EP-2491024-B1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-20 | — | — | EP | claimed |
| EP-2504333-A1 | MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-10-03 | — | — | EP | claimed |
| US-20120238561-A1 | MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-20 | — | — | US | claimed |
| WO-2012113850-A2 | (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-30 | — | — | WO | claimed |
| EP-2491024-A1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | claimed |
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | JANSSEN PHARMACEUTICA NV (BE) | 2012-07-05 | — | — | US | claimed |
| WO-2011064288-A1 | MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-03 | — | — | WO | claimed |
| WO-2011033018-A1 | SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-24 | — | — | WO | claimed |
| US-12594270-B2 | Schizophrenic disorder treatment using combination therapy | CAMBRIDGE COGNITION LIMITED (GB) | 2026-04-07 | — | — | US | disclosed |
| US-7732477-B2 | N-(1-azabicyclo[2.2.2]oct-3-yl)-heteroaryl carboxamides; alpha 7-nicotinic acetylcholine receptors (nAChR) agonists; improving perception, concentration, learning and memory; neuropathic pain; acute and chronic pain | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238561-A1 | MORPHOLINOTHIAZOLES AS ALPHA 7 POSITIVE ALLOSTERIC MODULATORS | CHRNA7, CHRNE, CHRNA1 | CHRNA7 1/4885HTR3A 284/4885POLB 3840/4885 |
| US-20190105315-A1 | COMPOSITIONS AND METHODS FOR TREATMENT RELATED TO FALL AND FALL FREQUENCY IN NEURODEGENERATIVE DISEASES | PARK7, BDNF, SNCA | CHRNA7 31/4885HTR3A 563/4885POLB 1170/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CHRNA7 83/4885HTR3A 6/4885POLB 3092/4885 |
| US-12594270-B2 | Schizophrenic disorder treatment using combination therapy | CHRNA7, HTR7, CHRNA10 | CHRNA7 1/4885HTR3A 5/4885POLB 3781/4885 |
| US-20120172354-A1 | Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines | CHRM1, CHRNA1, CHRM3 | CHRNA7 11/4885HTR3A 66/4885POLB 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.